Matinas BioPharma (MTNB) Investor Presentation - Slideshow

LNC Platform & Technology - Matinas BioPharma focuses on improving intracellular delivery of therapeutics using its Lipid Nanocrystal (LNC) delivery technology[4] - LNCs are differentiated from liposomes, LNPs, and viral vectors due to their unique structure, formulation goals, and potential applications, offering advantages like stability and the ability to deliver large molecules[23] - The LNC platform enables targeted delivery to activated cells through membrane fusion, phagocytosis, or endocytosis, leveraging phosphatidylserine (PS) for cellular targeting[27] MAT2203 (Oral Amphotericin B) - The global Amphotericin B market is approximately $800 million in 2018, with a potential for expansion to $6 billion within the invasive fungal infection market[50] - EnACT, a Phase 2 study in HIV patients with cryptococcal meningitis, is assessing the safety, tolerability, and efficacy of MAT2203, with enrollment >50% and on schedule[4, 62] MAT2501 (Oral Amikacin) - Matinas BioPharma received $3.75 million in funding from the Cystic Fibrosis Foundation to accelerate the development of MAT2501 for nontuberculous mycobacterial (NTM) disease[4, 74] - MAT2501 has the potential to become the first oral aminoglycoside, addressing a significant unmet need in the treatment of NTM infections, with 80,000-90,000 US NTM patients, 40% of whom are refractory to treatment[68] LYPDISO™ (MAT9001) - ENHANCE-IT study data demonstrated significantly higher plasma EPA concentrations with LYPDISO™ compared to Vascepa®, with a 46% relative percent increase change from baseline EPA level vs Vascepa®[85] - The ENHANCE-IT data supports the pursuit of a cardiovascular outcomes indication for LYPDISO™[87]